Intravenous immunoglobulin for severe sepsis and septic shock: Clinical effectiveness, cost-effectiveness and value of a further randomised controlled trial

Critical Care

Volumn 18, Issue 6, 2014, Pages

  Soares, Marta O ^a   Welton, Nicky J ^b   Harrison, David A ^c   Peura, Piia ^a   Shankar Hari, Manu ^d   Harvey, Sheila E ^c   Madan, Jason ^e   Ades, Anthony E ^b   Rowan, Kathryn M ^c   Palmer, Stephen J ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c King's College London   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN M;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; SEPTIC SHOCK; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; THERAPY EFFECT; AGED; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; FEMALE; MALE; MIDDLE AGED; PROCEDURES; SHOCK, SEPTIC; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS;

AGED; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPSIS; SHOCK, SEPTIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84927768670     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-014-0649-z     Document Type: Article

References (40)

1. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 2001:1250-1256. 10.1097/01.CCM.0000050454.01978.3B.
2. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41:580-637. 10.1097/CCM.0b013e31827e83af, 23353941.
3. Harrison DA, Welch CA, Eddleston JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care 2006, 10:R42. 10.1186/cc4854, 16542492.
4. Department of Health: Demand management plan for immunoglobulin use. In Demand management plan for immunoglobulin use. 2nd edition; 2008. [http://www.ivig.nhs.uk/documents/Demand_Management_Plan_SECOND_EDITION.pdf]..
5. Turgeon AF, Hutton B, Fergusson DA, McIntyre L, Tinmouth AA, Cameron DW, Hebert PC. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 2007, 146:193-203. 10.7326/0003-4819-146-3-200702060-00009, 17283351.
6. Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007, 35:2686-2692. 10.1097/01.CCM.0000295312.13466.1C, 18074465.
7. Alejandria MM, Lansang MA, Dans LF, Mantaring Iii JB. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev 2013, 9. 24043371.
8. Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007, 35:2677-2685. 10.1097/01.CCM.0000295263.12774.97, 18074464.
9. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ 1996, 5:513-524. 10.1002/(SICI)1099-1050(199611)5:6<513::AID-HEC237>3.0.CO;2-9, 9003938.
10. Soares M, Welton N, Harrison D, Peura P, Hari M, Harvey S, Madan J, Ades A, Palmer S, Rowan K. An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis. Health Technol Assess 2012, 16:1-186. 10.3310/hta16070.
11. National Institute for Health and Clinical Excellence: Guide to the methods of technology appraisal. [http://www.nice.org.uk/article/pmg9: NICE; 2004]..
12. Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health 2005, 8:1-2. 10.1111/j.1524-4733.2005.08101.x, 15841888.
13. Claxton K, Ginnelly L, Sculpher M, Philips Z, Palmer S. A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. Health Technol Assess 2004, 8:1-103. 10.3310/hta8310, 15248937.
14. Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation 2006, Oxford University Press, Oxford.
15. R Development Core Team: The R project for statistical computing. Vienna, Austria; The R Foundation for statistical computing. 2010. [http://www.r-project.org/].
16. Bernardo JM, Smith AFM. Bayesian Theory 1994, John Wiley & Sons Ltd, Chichester, UK; New York.
17. Gilks WR: Markov chain Monte Carlo. New York, NY; John Wiley & Sons, Ltd: In Encyclopedia of Biostatistics; 2005..
18. Lunn D, Spiegelhalter D, Thomas A, Best N. The BUGS project: evolution, critique and future directions. Stat Med 2009, 28:3049-3067. 10.1002/sim.3680, 19630097.
19. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - A Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000, 10:325-337. 10.1023/A:1008929526011.
20. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res 2001, 10:277-303. 10.1191/096228001678227794, 11491414.
21. Spiegelhalter D, Abrams K, Myles J. Bayesian approaches to clinical trials and health-care evaluation 2004, John Wiley & Sons, Ltd, West Sussex, UK.
22. Spiegelhalter DJ, Best NG, Carlin BP, Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Ser B (Stat Methodol) 2002, 64:583-639. 10.1111/1467-9868.00353.
23. Cuthbertson BH, Elders A, Hall S, Taylor J, MacLennan G, Mackirdy F, Mackenzie SJ. Mortality and quality of life in the five years after severe sepsis. Crit Care 2013, 17:R70. 10.1186/cc12616, 23587132.
24. Department of Health: NHS Reference costs 2007/08. In Book NHS Reference costs 2007/08. Department of Health; 2008. [http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_098945].
25. Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002, 347:993-1000. 10.1056/NEJMsa020969, 12324556.
26. Drabinski A, Williams G, Formica C. Observational evaluation of health state utilities among a cohort of sepsis patients. Value Health 2001, 4:128-129.
27. Rodriguez A, Rello J, Neira J, Maskin B, Ceraso D, Vasta L, Palizas F. Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock 2005, 23:298-304. 10.1097/01.shk.0000157302.69125.f8, 15803051.
28. Hentrich M, Fehnle K, Ostermann H, Kienast J, Cornely O, Salat C, Ubelacker R, Buchheidt D, Behre G, Hiddemann W, Schiel X. IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med 2006, 34:1319-1325. 10.1097/01.CCM.0000215452.84291.C6, 16540956.
29. Karatzas S, Boutzouka E, Venetsanou K, Myrianthefs P, Fildisis G, Baltopoulos G. The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis: another point of view. Crit Care 2002, 6:543-544. author reply 545, 10.1186/cc1837, 12512504.
30. Tugrul S, Ozcan PE, Akinci O, Seyhun Y, Cagatay A, Cakar N, Esen F. The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830]. Crit Care 2002, 6:357-362. 10.1186/cc1523, 12225613.
31. Behre G, Ostermann H, Schedel I, Helmerking M, Schiel X, Rothenburger M. Endotoxin concentrations and therapy with polyclonal IgM-enriched immunoglobulins in neutropenic cancer patients with sepsis syndrome: pilot study and interim analysis of a randomized trial. Anti Infect Drugs Chemother 1995, 13:129-134.
32. Schedel I, Dreikhausen U, Nentwig B, Hockenschnieder M, Rauthmann D, Balikcioglu S, Coldewey R, Deicher H. Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med 1991, 19:1104-1113. 10.1097/00003246-199109000-00003, 1884609.
33. Wesoly C, Kipping N, Grundmann R. Immunglobulintherapie der postoperativen sepsis. Z Exp Chir Transplant Kunstliche Organe 1990, 23:213-216. 2095647.
34. Spannbrucker N, Munch H, Kunze R, Vogel F: Auswirkungen von immunglobulinsubstitution bei sepsis.Intensivmedizin 1987, 6:314..
35. Dominioni L, Bianchi V, Imperatori A, Minoia G, Dionigi R. High-dose intravenous IgG for treatment of severe surgical infections. Dig Surg 1996, 13:430-434. 10.1159/000172479.
36. Burns ER, Lee V, Rubinstein A. Treatment of septic thrombocytopenia with immune globulin. J Clin Immunol 1991, 11:363-368. 10.1007/BF00918802, 1761642.
37. De Simone C, Delogu G, Corbetta G. Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients. Crit Care Med 1988, 16:23-26. 10.1097/00003246-198801000-00005, 3276446.
38. Werdan K, Pilz G, Bujdoso O, Fraunberger P, Neeser G, Schmieder RE, Viell B, Marget W, Seewald M, Walger P, Stuttmann R, Speichermann N, Peckelsen C, Kurowski V, Osterhues H-H, Verner L, Neumann R, Müller-Werdan U. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 2007, 35:2693-2701. 10.1097/01.CCM.0000295426.37471.79, 18074471.
39. Grundmann R, Hornung M. Immunoglobulin therapy in patients with endotoxemia and postoperative sepsis-a prospective randomized study. Prog Clin Biol Res 1988, 272:339-349. 3293080.
40. Yakut M, Cetiner S, Akin A, Tan A, Kaymakcioglu N, Simsek A. Sepsisdeki hastalarda immunglobulin G (IgG) kullaniminin mortalite oranina etkisi. GATA Bulteni 1998, 40:76-81.